BioMarin Pharmaceuticals BMRN Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $3.22B+12.9% | $2.85B+18.0% | $2.42B+15.4% | $2.1B+13.5% | ||
| $717.44M+23.6% | $580.24M+9.1% | $532.06M+5.8% | $503.02M+6.9% | ||
| $2.5B+10.1% | $2.27B+20.5% | $1.89B+18.5% | $1.59B+15.8% | ||
| 77.7%-1.9pp | 79.7%+1.7pp | 78%+2.0pp | 76%+1.5pp | ||
| $921.93M+23.4% | $747.18M+0.1% | $746.77M+15.0% | $649.61M+3.3% | ||
| $1.15B+14.3% | $1.01B+13.1% | $892.41M+8.4% | $823.24M+8.4% | ||
| $2.81B+18.7% | $2.37B+6.1% | $2.23B+15.4% | $1.94B+0.3% | ||
| —— | $484.21M+161% | $185.77M+6.7% | $174.06M+311% | ||
| $10.9M-14.0% | $12.67M-26.9% | $17.34M+8.5% | $15.97M+4.1% | ||
| —— | —— | —— | —— | ||
| $509.63M-5.9% | $541.76M+187% | $188.56M— | —— | ||
| $133.58M+16.3% | $114.9M+423% | $21.97M— | —— | ||
| —— | $426.86M+155% | $167.65M+18.2% | $141.81M+321% | ||
| —— | $2.21+154% | $0.87+16.0% | $0.75+308% | ||
| $536.42M-7.6% | $580.64M+100% | $290.16M+5.1% | $276.03M+974% | ||
| 16.7%-3.7pp | 20.3%+8.4pp | 12%-1.2pp | 13.2%+11.8pp | ||
| $456.87M-5.6% | $484.21M+161% | $185.77M+6.7% | $174.06M+311% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is BioMarin Pharmaceuticals's revenue?
- BioMarin Pharmaceuticals (BMRN) generated $3.2B in revenue over the trailing twelve months, up 9.9% year over year.
- Is BioMarin Pharmaceuticals profitable?
- BioMarin Pharmaceuticals reported $501.0M in net income over the trailing twelve months, a 16.8% net margin.
- What are BioMarin Pharmaceuticals's profit margins?
- Gross margin is 76.5% and operating margin is 19.9%, with a 16.8% net margin.
- What is BioMarin Pharmaceuticals's earnings per share?
- BioMarin Pharmaceuticals's diluted EPS over the trailing twelve months is $2.56.
- Where does BioMarin Pharmaceuticals's income statement data come from?
- Every line is extracted from BioMarin Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
